Tanai Therapeutics: what changed
What changed
Tanai Therapeutics
NACE 72.101, Research and development on biotechnology
filed annual accounts (NBB)
Net result for the year
-€2.5m
2024 · -€1.8m-€683,133
Equity
€3.6m
2024 · €6.0m-€2.5m
Cash
€2.7m
2024 · €4.8m-€2.1m
Balance sheet total
€3.9m
2024 · €6.1m-€2.3m
Largest movements
Assets
- Cash -€2.1m
down €2.1m (-43.1%), from €4.8m to €2.7m
mainly Net result for the year (-€2.5m) and Investment in fixed assets (net) (-€1.8m)
- Intangible fixed assets -€300,000
down €300,000 (-26.1%), from €1.2m to €850,000
Equity and liabilities
- Profit (loss) carried forward -€2.5m
down €2.5m (-138%), from -€1.8m to -€4.3m
- Trade debts +€234,098
up €234,098 (+287%), from €81,669 to €315,766
Income statement
- Gross operating margin -€303,393
down €303,393 (-135%), from -€224,811 to -€528,205
- Depreciation +€288,961
up €288,961 (+16.5%), from €1.8m to €2.0m
- Financial income -€47,237
down €47,237 (-50.7%), from €93,197 to €45,960
- Taxes +€39,531
up €39,531 (+46.7%), from -€84,651 to -€45,120
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
-€1.8m
Gross operating margin
-€303,393
Depreciation
-€288,961
Other operating charges
+€228
Financial income
-€47,237
Financial charges
-€4,239
Taxes
-€39,531
Result 2025
-€2.5m
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
-€290,662
Investment
-€1.8m
Financing
€0
Cash 2024
€4.8m
From operations (derived)
-€290,662
Net result for the year
-€2.5m
Depreciation
+€2.0m
Receivables after one year
-€58,843
Receivables within one year
-€4,381
Deferred charges and accrued income
-€18,437
Trade debts
+€234,098
Investment (derived)
-€1.8m
Investment in fixed assets (net)
-€1.8m
Cash 2025
€2.7m
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €6,126,687 | €3,872,669 | -€2.3m | -36.8% |
| Fixed assets | 21/28 | €1,150,000 | €883,694 | -€266,306 | -23.2% |
| Intangible fixed assets | 21 | €1,150,000 | €850,000 | -€300,000 | -26.1% |
| Tangible fixed assets | 22/27 | - | €33,694 | +€33,694 | |
| Plant, machinery and equipment | 23 | - | €27,731 | +€27,731 | |
| Furniture and vehicles | 24 | - | €5,964 | +€5,964 | |
| Current assets | 29/58 | €4,976,687 | €2,988,975 | -€2.0m | -39.9% |
| Amounts receivable after more than one year | 29 | €112,610 | €171,452 | +€58,843 | +52.3% |
| Other amounts receivable | 291 | €112,610 | €171,452 | +€58,843 | +52.3% |
| Amounts receivable within one year | 40/41 | €67,999 | €72,381 | +€4,381 | +6.4% |
| Other amounts receivable | 41 | €67,999 | €72,381 | +€4,381 | +6.4% |
| Cash at bank and in hand | 54/58 | €4,796,078 | €2,726,706 | -€2.1m | -43.1% |
| Deferred charges and accrued income | 490/1 | - | €18,437 | +€18,437 | |
| Total equity and liabilities | 10/49 | €6,126,687 | €3,872,669 | -€2.3m | -36.8% |
| Equity | 10/15 | €6,045,018 | €3,556,903 | -€2.5m | -41.2% |
| Contributions | 10/11 | €7,850,000 | €7,850,000 | = | 0.0% |
| Capital | 10 | €7,850,000 | €7,850,000 | = | 0.0% |
| Issued capital | 100 | €7,850,000 | €7,850,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€1,804,982 | -€4,293,097 | -€2.5m | -138% |
| Amounts payable | 17/49 | €81,669 | €315,766 | +€234,098 | +287% |
| Amounts payable within one year | 42/48 | €81,669 | €315,766 | +€234,098 | +287% |
| Trade debts | 44 | €81,669 | €315,766 | +€234,098 | +287% |
| Suppliers | 440/4 | €81,669 | €315,766 | +€234,098 | +287% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,756,054 | €2,045,016 | +€288,961 | +16.5% |
| Other operating charges | 640/8 | €772 | €544 | -€228 | -29.5% |
| Gross operating margin | 9900 | -€224,811 | -€528,205 | -€303,393 | -135% |
| Operating profit (loss) | 9901 | -€1,981,638 | -€2,573,764 | -€592,127 | -29.9% |
| Financial income | 75/76B | €93,197 | €45,960 | -€47,237 | -50.7% |
| Recurring financial income | 75 | €93,197 | €45,960 | -€47,237 | -50.7% |
| Financial charges | 65/66B | €1,192 | €5,431 | +€4,239 | +356% |
| Recurring financial charges | 65 | €1,192 | €5,431 | +€4,239 | +356% |
| Profit (loss) for the period before taxes | 9903 | -€1,889,633 | -€2,533,235 | -€643,602 | -34.1% |
| Income taxes | 67/77 | -€84,651 | -€45,120 | +€39,531 | +46.7% |
| Profit (loss) for the period | 9904 | -€1,804,982 | -€2,488,115 | -€683,133 | -37.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,804,982 | -€2,488,115 | -€683,133 | -37.8% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 5 November 2026 via checked.be.